Every surgical robotics company launching right now is making the same argument.
Superior precision. Shorter recovery. Lower complication rates. The clinical data is rigorous. The surgeon presentations are compelling. The procurement conversations are structured and evidence-led.
And almost none of them are asking the question that actually determines whether a robotic surgery programme succeeds in market: do patients know this exists? Do they know to ask for it? Does the clinic running the technology have any infrastructure for attracting them?
In most cases, the answer is no. And that's not an oversight. It's the consequence of something structural that healthcare has been living with for thirty years and surgical robots are about to expose.
The conventional response
When a MedTech product underperforms in market, the investigation follows a predictable path.
Territory coverage gets reviewed. Call rates go up. Sales force effectiveness gets measured. The conversion funnel gets mapped from first contact to close. The clinical champion gets identified, briefed, and invited to speak at a conference.
The marketing response mirrors the sales response. Badge scans at events. Brand presence at congresses. A product brochure the sales team can leave in the room. Clinical content that supports the conversation the surgeon is already having.
This approach makes sense if your buyer is the surgeon. It made complete sense for twenty years, because the surgeon was the buyer and the patient followed. If a clinical champion says this product is superior, the system routes patients toward it. Sales tells the surgeon, the surgeon tells the patient. Job done.
That model still works in some categories. In elective procedures, it's been breaking down for a decade. The reason is straightforward: patients research.
Why it doesn't work for robotics
The population of people facing elective surgery behaves like any other research-active consumer. They search for their condition. They look for comparisons between treatment options. They read patient forums. They watch videos. They consult people they trust before they consult their surgeon.
This isn't a trend. It's been measurable since smartphones became ubiquitous. What changed was the rate at which patients arrive with a formed opinion, not whether they form one.
Surgical robots sit squarely in this category. A patient told they need knee replacement surgery is likely to search for "knee replacement types", "recovery from knee surgery", "robotic knee replacement". If the clinic they're referred to runs robotic surgery and the patient never finds that out through their own research, the clinic loses the patient who would have chosen it specifically because of the technology.
The clinical champion, doing what clinical champions do (attending conferences, writing papers, presenting at training days), reaches other surgeons. They don't reach the patient. And the company supplying the robot has typically built nothing to support the clinic's ability to do so either.
The result: the robot sits in a theatre doing fewer procedures than its capital cost justifies, because the patient funnel was never built.
What's actually happening
Here's the structural issue that sits underneath this.
MedTech's marketing function is, in most cases, a sales support function. It was built that way, for sensible historical reasons, and it has never fundamentally changed.
The people occupying marketing roles in most MedTech organisations today came from adjacent functions. Product managers who moved sideways when the commercial structure changed. Salespeople who transitioned into marketing when the territory model shifted. Medical science liaisons who became communications leads. Brand managers hired from agencies who learned the clinical context on the job.
These are not bad hires. Many of them are exceptionally capable people. The issue is the brief they were trained for.
A product manager in a marketing role knows the product inside out. They understand the clinical pathway, the competitive positioning, the surgeon preference data. They know how to support a sales conversation and build the collateral that reinforces it.
They were not trained to build a patient demand generation system. That requires a different set of skills: understanding the patient decision journey, building content that's accessible and compliant, running multi-channel campaigns that reach people before they've been referred, analysing where patients come from and what moved them to act. These are marketing disciplines. They're not product management disciplines, and they're not sales disciplines.
The brief has changed. The hire hasn't caught up.
(It's worth saying this clearly: this is an industry-wide structural observation, not a critique of the individuals in these roles. Most of them are doing exactly what the organisation asks. The problem is what the organisation has been asking for.)
A different approach
The companies that win in surgical robotics over the next decade will not be the ones with the best clinical evidence. All the major players will have strong clinical evidence. The differentiator will be who builds the patient marketing infrastructure first.
This does not require building a consumer marketing function from scratch. It requires building specific capabilities that sit between the clinical evidence the company already has and the patient demand the clinic needs.
What that looks like in practice:
Starting with the patient decision journey. Before building anything, understand how patients in the relevant clinical category actually search, research, and decide. What questions do they ask? What sources do they trust? What would move them from passive awareness to an active request for a specific type of procedure? This is primary research, not assumption.
Building a compliant patient education asset library. Content that can be used by clinic partners, that passes regulatory sign-off in each relevant market, that addresses the patient's actual questions rather than the surgeon's. This content lives on the clinic's website and patient portal, not the company's. The company's role is to produce it and make it easy to deploy.
Establishing referral pathway analytics. Understanding where patients come from for robotic procedures at pilot sites. Are they self-referring after online research? Coming through GP referrals? Arriving because of word of mouth from previous patients? Without this data, the company can't make an evidence-based argument for what to do more of.
Developing patient-facing clinical voice. Not every clinical champion is willing or able to speak to a patient audience rather than a surgical one. But some are. A surgeon willing to say publicly, in accessible language, why they chose a robotic platform and what their patients experience differently, is worth more than any copy written on their behalf.
Starting search engine visibility now. The search landscape for robotic surgery is not yet crowded. The brands and clinics that begin building organic search presence for relevant patient queries today will hold an advantage that compounds over two to three years. Most are not doing this.
Case study
A surgical device company came to us eighteen months after a product launch that had technically succeeded clinically and commercially stalled.
The product had strong outcomes data. Surgeons who had used it were positive. Procurement committees in two major hospital networks had approved it. The sales team had done everything right.
The product was under-utilised. The surgical teams who had it weren't running the volume of procedures the capital investment justified. The simple reason: the patient funnel hadn't been built. Patients weren't requesting the procedure. GPs weren't referring into it. The clinic didn't have the materials or digital infrastructure to explain the technology to incoming patients.
We worked backwards from the patient's question. What would someone diagnosed with the relevant condition search for? What content did they find? What would move them from passive research to an active conversation with their GP about a robotic surgical option?
Six months after rebuilding the patient-facing infrastructure, two of the four pilot sites were over-subscribed. The clinical evidence hadn't changed. The product hadn't changed. The patient pathway had.
The company's commercial conversation with the remaining hospital networks shifted. Instead of arguing about procedure volumes in the abstract, they could point to two sites where the patient demand infrastructure was running and quantify the difference.
Practical first steps
If you're leading marketing for a company with surgical robotics in the product portfolio, these are the first things worth doing, roughly in order.
Map the patient decision journey before building anything. Commission primary research if you don't have it. Talk to patients who have been through the relevant surgical pathway. Understand their information-seeking behaviour. Most companies skip this and build content based on what they think patients want to know rather than what patients actually ask.
Audit what your clinic partners have. Most clinic websites have generic patient information for common procedures. Very few have specific patient content about robotic surgery. You are in a position to provide that content. Your clinic partner is the distribution point. That's an unusually clean content partnership with obvious commercial upside.
Find one pilot site willing to measure the patient pathway. Set up referral tracking, search analytics, and patient-reported source data at one clinic. Run it for six months. The data you generate is the commercial argument for every subsequent conversation.
Identify regulatory requirements per market before producing anything. Patient-facing content in healthcare is regulated. The specific requirements vary by country and clinical category. Build the compliance infrastructure first, not after you've produced a library of content that can't be approved.
Start building organic search presence now. Even if everything else is twelve months away, the SEO work can begin. Identify the search queries your target patients use. Understand what currently ranks. Start producing content that addresses those questions. The compounding effect of search visibility means that starting twelve months later is not a twelve-month disadvantage. It's a two to three year disadvantage.
The real stakes
Surgical robotics is not a niche category. The market is growing faster than almost any other segment in medical devices. The companies entering it are investing heavily in clinical evidence, in surgeon training, in procurement relationships.
The companies that win the next decade of surgical robotics won't be the ones that outperform on clinical evidence alone. They'll be the ones that figure out how to build patient demand for the procedures their technology enables.
That requires a marketing capability most MedTech organisations don't currently have.
The question worth asking now, before the market matures and the window closes, is whether to build that capability or remain dependent on a clinical champion and a sales force doing work that was never really their job.
MedTech is catching up with pharma. Surgical robots are the forcing function.
Not sure where your patient marketing capability sits? The 10-minute assessment at agencymedicalmarketing.com/assessments/patient-marketing scores you across five categories and tells you what to build first. Free. No email required.
What next?